MINERVA SURGICAL INC (UTRS) Stock Fundamental Analysis

NASDAQ:UTRS • US60343F2056

1.48 USD
-0.07 (-4.52%)
At close: Dec 28, 2023
1.53 USD
+0.05 (+3.38%)
After Hours: 12/28/2023, 8:06:43 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Overall UTRS gets a fundamental rating of 2 out of 10. We evaluated UTRS against 185 industry peers in the Health Care Equipment & Supplies industry. UTRS may be in some trouble as it scores bad on both profitability and health. UTRS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • UTRS had negative earnings in the past year.
  • UTRS had a negative operating cash flow in the past year.
UTRS Yearly Net Income VS EBIT VS OCF VS FCFUTRS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 -10M -20M -30M -40M -50M

1.2 Ratios

  • UTRS has a Return On Assets of -45.95%. This is in the lower half of the industry: UTRS underperforms 66.17% of its industry peers.
  • With a Return On Equity value of -164.78%, UTRS is not doing good in the industry: 77.11% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -45.95%
ROE -164.78%
ROIC N/A
ROA(3y)-29.33%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
UTRS Yearly ROA, ROE, ROICUTRS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 0 50 -50 -100 -150

1.3 Margins

  • With a Gross Margin value of 54.19%, UTRS perfoms like the industry average, outperforming 50.75% of the companies in the same industry.
  • In the last couple of years the Gross Margin of UTRS has grown nicely.
  • The Profit Margin and Operating Margin are not available for UTRS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 54.19%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.06%
GM growth 5YN/A
UTRS Yearly Profit, Operating, Gross MarginsUTRS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 0 50 -50 -100 -150 -200

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • UTRS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, UTRS has more shares outstanding
  • UTRS has a worse debt/assets ratio than last year.
UTRS Yearly Shares OutstandingUTRS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 500K 1M
UTRS Yearly Total Debt VS Total AssetsUTRS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 20M 40M 60M 80M 100M

2.2 Solvency

  • UTRS has an Altman-Z score of -6.13. This is a bad value and indicates that UTRS is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of UTRS (-6.13) is worse than 70.65% of its industry peers.
  • UTRS has a Debt/Equity ratio of 1.37. This is a high value indicating a heavy dependency on external financing.
  • UTRS has a Debt to Equity ratio of 1.37. This is amonst the worse of the industry: UTRS underperforms 82.59% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.37
Debt/FCF N/A
Altman-Z -6.13
ROIC/WACCN/A
WACC8.14%
UTRS Yearly LT Debt VS Equity VS FCFUTRS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 0 50M -50M

2.3 Liquidity

  • A Current Ratio of 1.88 indicates that UTRS should not have too much problems paying its short term obligations.
  • UTRS has a worse Current ratio (1.88) than 75.62% of its industry peers.
  • UTRS has a Quick Ratio of 1.02. This is a normal value and indicates that UTRS is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Quick ratio value of 1.02, UTRS is not doing good in the industry: 81.09% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.88
Quick Ratio 1.02
UTRS Yearly Current Assets VS Current LiabilitesUTRS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • UTRS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 58.66%, which is quite impressive.
  • Looking at the last year, UTRS shows a small growth in Revenue. The Revenue has grown by 3.07% in the last year.
  • The Revenue has been growing by 24.58% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)58.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.88%
Revenue 1Y (TTM)3.07%
Revenue growth 3Y24.58%
Revenue growth 5YN/A
Sales Q2Q%-4.92%

3.2 Future

  • The Earnings Per Share is expected to grow by 23.40% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 10.85% on average over the next years. This is quite good.
EPS Next Y82.41%
EPS Next 2Y36.93%
EPS Next 3Y23.4%
EPS Next 5YN/A
Revenue Next Year2.99%
Revenue Next 2Y8.86%
Revenue Next 3Y10.85%
Revenue Next 5YN/A

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
UTRS Yearly Revenue VS EstimatesUTRS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
UTRS Yearly EPS VS EstimatesUTRS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 -20 -40 -60

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • UTRS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year UTRS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
UTRS Price Earnings VS Forward Price EarningsUTRS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
UTRS Per share dataUTRS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5

4.3 Compensation for Growth

  • UTRS's earnings are expected to grow with 23.40% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.93%
EPS Next 3Y23.4%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • UTRS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

MINERVA SURGICAL INC

NASDAQ:UTRS (12/28/2023, 8:06:43 PM)

After market: 1.53 +0.05 (+3.38%)

1.48

-0.07 (-4.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-13
Earnings (Next)03-19
Inst Owners0.31%
Inst Owner Change0%
Ins Owners1799.28%
Ins Owner Change0%
Market Cap13.14M
Revenue(TTM)51.69M
Net Income(TTM)-33.45M
Analysts82.86
Price Target3.06 (106.76%)
Short Float %0%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.06%
Min EPS beat(2)20.59%
Max EPS beat(2)45.53%
EPS beat(4)3
Avg EPS beat(4)16.45%
Min EPS beat(4)-6.95%
Max EPS beat(4)45.53%
EPS beat(8)5
Avg EPS beat(8)7.58%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-8.42%
Min Revenue beat(2)-11.14%
Max Revenue beat(2)-5.7%
Revenue beat(4)1
Avg Revenue beat(4)-3.51%
Min Revenue beat(4)-11.14%
Max Revenue beat(4)4.81%
Revenue beat(8)1
Avg Revenue beat(8)-2.78%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-85%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1250%
EPS NY rev (1m)0%
EPS NY rev (3m)-1750%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.99%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.37%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.25
P/FCF N/A
P/OCF N/A
P/B 0.65
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-8.21
EYN/A
EPS(NY)-2.95
Fwd EYN/A
FCF(TTM)-4.37
FCFYN/A
OCF(TTM)-4.36
OCFYN/A
SpS5.82
BVpS2.29
TBVpS-0.23
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -45.95%
ROE -164.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 54.19%
FCFM N/A
ROA(3y)-29.33%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.06%
GM growth 5YN/A
F-Score2
Asset Turnover0.71
Health
Industry RankSector Rank
Debt/Equity 1.37
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.57%
Cap/Sales 0.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.88
Quick Ratio 1.02
Altman-Z -6.13
F-Score2
WACC8.14%
ROIC/WACCN/A
Cap/Depr(3y)4.15%
Cap/Depr(5y)N/A
Cap/Sales(3y)0.81%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.88%
EPS Next Y82.41%
EPS Next 2Y36.93%
EPS Next 3Y23.4%
EPS Next 5YN/A
Revenue 1Y (TTM)3.07%
Revenue growth 3Y24.58%
Revenue growth 5YN/A
Sales Q2Q%-4.92%
Revenue Next Year2.99%
Revenue Next 2Y8.86%
Revenue Next 3Y10.85%
Revenue Next 5YN/A
EBIT growth 1Y9.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year43.05%
EBIT Next 3Y11.17%
EBIT Next 5YN/A
FCF growth 1Y-185.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-198.46%
OCF growth 3YN/A
OCF growth 5YN/A

MINERVA SURGICAL INC / UTRS FAQ

Can you provide the ChartMill fundamental rating for MINERVA SURGICAL INC?

ChartMill assigns a fundamental rating of 2 / 10 to UTRS.


What is the valuation status for UTRS stock?

ChartMill assigns a valuation rating of 1 / 10 to MINERVA SURGICAL INC (UTRS). This can be considered as Overvalued.


What is the profitability of UTRS stock?

MINERVA SURGICAL INC (UTRS) has a profitability rating of 1 / 10.


Can you provide the financial health for UTRS stock?

The financial health rating of MINERVA SURGICAL INC (UTRS) is 1 / 10.